

PROJECT Asthma-Study.

Continued from Page

Sensitization BALB/c mice - exp.

BALB/c From Jackson Laboratory.

BALB/c	DOB	Weight(g)	Route of administration	Dose of sensitization	Alum	Sensitization time	Sensitization time
386	11/26/01	23.6	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
387	11/26/01	24.4	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
388	11/26/01	25	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
389	11/26/01	21.8	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
390	11/26/01	24.8	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
391	11/26/01	22.7	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
392	11/26/01	24.1	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
383	11/26/01	22.7	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
384	11/26/01	24.8	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
385	11/26/01	26.4	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
386	11/26/01	25.8	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
387	11/26/01	23.3	i.p.	20ug OVA	2mg	2/18/02(day1)	3/4/02(day14)
388C	11/26/01	22.4	i.p.	PBS	2mg	2/18/02(day1)	3/4/02(day14)
389C	11/26/01	26.1	i.p.	PBS	2mg	2/18/02(day1)	3/4/02(day14)
400C	11/26/01	26.4	i.p.	PBS	2mg	2/18/02(day1)	3/4/02(day14)

Alway challenge dose	Alway challenge time	Alway challenge time	Alway challenge time
1% OVA/min	3/18/02(day28)	3/19/02(day29)	3/20/02(day30)
1% OVA/min	3/18/02(day28)	3/19/02(day29)	3/20/02(day30)
1% OVA/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)
1% OVA/min	3/18/02(day28)	3/19/02(day29)	3/20/02(day30)
1% OVA/min	3/18/02(day28)	3/19/02(day29)	3/20/02(day30)
1% OVA/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)
1% OVA/min	3/18/02(day28)	3/19/02(day29)	3/20/02(day30)
1% OVA/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)
1% OVA/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)
1% OVA/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)
1% OVA/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)
PBS/min	3/18/02(day28)	3/19/02(day29)	3/20/02(day30)
PBS/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)
PBS/min	3/19/02(day28)	3/20/02(day29)	3/21/02(day30)

Preparation OVA Solution:

320 ml OVA

{ 704 ml Alum

544 ml PBS

Control

270 ml PBS

22 ml Alum

No > 161

Stir 30 min

lot # AE40391

continued on page

Read with 40x 15mm eyeglasses

T. P. 3/14/02
Signed Dateveg
lmmek9/15/02
Jen

Asthma Study

Schedule of experiment 1.

2/18/02 Monday day1 3/4/02 Monday day14 3/15/02 Friday day25 Treatment group1 anti-CS, dex control antibody 6 mice

3/18/02 Saturday day26 Treatment group2 anti-CS, dex control antibody 6 mice

3/18/02 Monday day28 challenge 1%OVA 10 min group1 measure 15min & 4h

3/19/02 Tuesday day29 challenge 1%OVA 10 min & Treat group1 measure 15min & 4h

3/20/02 Wednesday day30 challenge 1%OVA 10 min group2 measure 15min & 4h

Treat group2

3/21/02 Thursday day31 challenge 1%OVA 10 min group2 measure 15min & 4h

3/22/02 Friday day32 Treat group1

3/23/02 Saturday day33 treat group2

3/24/02 Monday day34 challenge 1%OVA 10 min group1 measure 15min & 4h BAL

3/25/02 Tuesday day35 challenge 1%OVA 10 min group2 measure 15min & 4h BAL

3/26/02 Wednesday day36 challenge 1%OVA 10 min group2 measure 15min & 4h BAL

BALB/c	DOB	Weight(g)	Route of administration	Dose of sensitization	Alum	Systmic time	Systmic time
431	11/28/01	26.1	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
432	11/28/01	26.3	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
433	11/28/01	27.3	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
434	11/28/01	27.3	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
436	11/28/01	26.9	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
437	11/28/01	25.4	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
438	11/28/01	24.5	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
439	11/28/01	29.1	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
440	11/28/01	27.2	I.p.	20ug OVA	2mg	3/4/02(day1)	3/18/02(day14)
443	11/26/01	28.8	I.p.	PBS	2mg	3/4/02(day1)	3/18/02(day14)
444	11/26/01	27.6	I.p.	PBS	2mg	3/4/02(day1)	3/18/02(day14)
445	11/26/01	26.1	I.p.	PBS	2mg	3/4/02(day1)	3/18/02(day14)

Last treatment date

Days after last treatment date

T1/23

3/14/02

wsd

9/25/02